Praxis faces Sept. 27 FDA decision on relutrigine while its own trial still enrolls
The PDUFA date for relutrigine in SCN2A/SCN8A epilepsy lands two months before the Phase 3 EMERALD trial's own primary completion date, leaving the confirmatory readout to trail the regulatory decision.
Executive Summary
- Praxis Precision Medicines is approaching a binary FDA approval decision for relutrigine in a genetically defined pediatric epilepsy population, running on a priority review timeline that compresses the standard review window.
- The application under review draws on an earlier-stage relutrigine study, not the ongoing registrational Phase 3 trial, which is still recruiting and will not produce its own topline data until after the FDA acts.
- The program carries Breakthrough Therapy and Orphan Drug designations from US and European regulators, signals of an unmet-need population with no approved disease-modifying option, though those designations do not by themselves determine the review outcome.
- The mechanism faces essentially no direct clinical competitor in this precise genetic population, leaving relutrigine to define, rather than follow, the standard of care if it clears.
The decision
The FDA accepted Praxis's new drug application for relutrigine under priority review and set a target action date of September 27, 2026. The application covers SCN2A- and SCN8A-related developmental and epileptic encephalopathies, rare genetic epilepsies that emerge in early childhood. Relutrigine is an oral small molecule designed to modulate sodium channels, targeting Nav1.2 and Nav1.6 activity linked to SCN2A and SCN8A mutations. The FDA granted the program Breakthrough Therapy Designation, and it also holds Orphan Drug and Breakthrough Therapy designations from the European Medicines Agency. PraxisPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ...May 7, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The confirmatory trial runs behind
Separate from the NDA under review, Praxis is running EMERALD (NCT07010471), a randomized, placebo-controlled Phase 3 trial testing relutrigine's effect on seizure frequency across a broader DEE population, with a target enrollment of 160 pediatric participants across the United States, Brazil, and Australia. The trial remains in Recruiting status, and its primary completion date has moved twice since the study began, from April 2026 to July 2026 and then to December 2026. Praxis has separately guided to topline EMERALD results in the fourth quarter of 2026, after the PDUFA date. The NDA's approval basis rests on the company's earlier-stage relutrigine data rather than on EMERALD, which functions as a distinct confirmatory readout for the broader DEE population rather than as evidence supporting this specific decision. NCT07010471+1A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ...May 7, 2026
The stake
“This quarter marks yet another inflection point for Praxis, with FDA acceptance of NDAs for both ulixacaltamide and relutrigine, positioning us for two U.S. launches within the next eight months,” said Marcio Souza, president and chief executive officer. Praxis also disclosed data from its EMBRAVE Part A study of a separate antisense candidate, elsunersen, showing a 77% placebo-adjusted reduction in monthly seizures in early-onset SCN2A-DEE, underscoring the sponsor's broader bet on this genetic epilepsy franchise beyond relutrigine alone. PraxisPraxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ...May 7, 2026
Competitive field
Only one other active industry trial targets Nav1.2 in developmental and epileptic encephalopathies, and no completed or terminated trial in that target-indication pairing has been recorded, leaving relutrigine without a resolved head-to-head precedent to benchmark against. The nearest disclosed comparators in the broader DEE space, including Longboard Pharmaceuticals' bexicaserin and Praxis's own earlier PRAX-562 program, work through different mechanisms, a serotonin receptor modulator and a distinct sodium-channel candidate, rather than sharing relutrigine's specific target profile. With no validated disease-modifying therapy approved in this genetically defined population, a clearance that reaches the broader SCN2A/SCN8A-DEE population, rather than a narrower subset, would be the outcome that most changes the competitive landscape. NCT07010471A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471
Sponsor track record
Praxis has completed four of five trials it has run to date, with one terminated, and the sponsor's broader 15-trial pipeline currently carries six recruiting studies alongside four completed ones. EMERALD's enrollment target has held steady at 160 participants without change, consistent with routine operational execution rather than a distressed program. Praxis+1Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial ...May 7, 2026A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of RelutrigineNCT07010471
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.